Literature DB >> 16540663

Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.

Xiaokui Yang1, Michael Fraser, Ute M Moll, Ajoy Basak, Benjamin K Tsang.   

Abstract

Akt is a determinant of cisplatin [cis-diammine-dichloroplatinum (CDDP)] resistance in ovarian cancer cells, and this may be related to the regulation of p53. Precisely how Akt facilitates CDDP resistance and interacts with p53 is unclear. Apoptotic stimuli induce second mitochondria-derived activator of caspase (Smac) release from mitochondria into the cytosol, where it attenuates inhibitor of apoptosis protein-mediated caspase inhibition. Whereas Smac release is regulated by p53 via the transactivation of proapoptotic Bcl-2 family members, it is unclear whether p53 also facilitates Smac release via its direct mitochondrial activity. Here we show that CDDP induces mitochondrial p53 accumulation, the mitochondrial release of Smac, cytochrome c, and HTR/Omi, and apoptosis in chemosensitive but not in resistant ovarian cancer cells. Smac release was p53 dependent and was required for CDDP-induced apoptosis. Mitochondrial p53 directly induced Smac release. Akt attenuated mitochondrial p53 accumulation and Smac/cytochrome c/Omi release and conferred resistance. Inhibition of Akt facilitated Smac release and sensitized chemoresistant cells to CDDP in a p53-dependent manner. These results suggest that Akt confers resistance, in part, by modulating the direction action of p53 on the caspase-dependent mitochondrial death pathway. Understanding the precise etiology of chemoresistance may improve treatment for ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16540663     DOI: 10.1158/0008-5472.CAN-05-0425

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  109 in total

1.  Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients.

Authors:  Meng Chen; Jian Gu; George L Delclos; Ann M Killary; Zhen Fan; Michelle A T Hildebrandt; Robert M Chamberlain; H Barton Grossman; Colin P Dinney; Xifeng Wu
Journal:  Carcinogenesis       Date:  2010-06-07       Impact factor: 4.944

2.  Proapoptotic protein Smac mediates apoptosis in cisplatin-resistant ovarian cancer cells when treated with the anti-tumor agent AT101.

Authors:  Wenbin Hu; Fang Wang; Jingsheng Tang; Xinyu Liu; Zhu Yuan; Chunlai Nie; Yuquan Wei
Journal:  J Biol Chem       Date:  2011-11-03       Impact factor: 5.157

3.  The important application of thioridazine in the endometrial cancer.

Authors:  Qiong Meng; Xiao Sun; Jing Wang; Yudong Wang; Lihua Wang
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

4.  Reduction of hyaluronan-CD44-mediated growth, migration, and cisplatin resistance in head and neck cancer due to inhibition of Rho kinase and PI-3 kinase signaling.

Authors:  Carlos Torre; Steven J Wang; Weiliang Xia; Lilly Y W Bourguignon
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2010-05

5.  Sequential application of a cytotoxic nanoparticle and a PI3K inhibitor enhances antitumor efficacy.

Authors:  Ashish Kulkarni; Bhaskar Roy; Ambarish Pandey; Aaron Goldman; Sasmit Sarangi; Poulomi Sengupta; Colin Phipps; Jawahar Kopparam; Michael Oh; Sudipta Basu; Mohammad Kohandel; Shiladitya Sengupta
Journal:  Cancer Res       Date:  2013-10-11       Impact factor: 12.701

Review 6.  Beyond chemotherapy: targeted therapies in ovarian cancer.

Authors:  Timothy A Yap; Craig P Carden; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

7.  MiR-514 attenuates proliferation and increases chemoresistance by targeting ATP binding cassette subfamily in ovarian cancer.

Authors:  Sha Xiao; Ming Zhang; Chang Liu; Deling Wang
Journal:  Mol Genet Genomics       Date:  2018-05-11       Impact factor: 3.291

8.  Nanog signaling in cancer promotes stem-like phenotype and immune evasion.

Authors:  Kyung Hee Noh; Bo Wook Kim; Kwon-Ho Song; Hanbyoul Cho; Young-Ho Lee; Jin Hee Kim; Joon-Yong Chung; Jae-Hoon Kim; Stephen M Hewitt; Seung-Yong Seong; Chih-Ping Mao; T-C Wu; Tae Woo Kim
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

9.  Molecular imaging reveals a role for AKT in resistance to cisplatin for ovarian endometrioid adenocarcinoma.

Authors:  Hanxiao Wang; Stefanie Galbán; Rong Wu; Brittany M Bowman; Amanda Witte; Katrin Vetter; Craig J Galbán; Brian D Ross; Kathleen R Cho; Alnawaz Rehemtulla
Journal:  Clin Cancer Res       Date:  2012-10-24       Impact factor: 12.531

10.  Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling.

Authors:  Liyun Cao; Daniela N Petrusca; Minati Satpathy; Harikrishna Nakshatri; Irina Petrache; Daniela Matei
Journal:  Carcinogenesis       Date:  2008-07-29       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.